 STOCKHOLM, Oct. 15, 2021 PRNewswire -- Swedish Orphan Biovitrum AB publ SobiTM STO:SOBI and Apellis Pharmaceuticals, Inc. Nasdaq: APLS announce today that the Committee for Medicinal Products for Human Use CHMP of the European Medicines Agency has adopted a positive opinion recommending the marketing authorisation of Aspaveli pegcetacoplan for the treatment of adults with paroxysmal nocturnal haemoglobinuria PNH who are anaemic after treatment with a C5 inhibitor for at least three months. The positive opinion from the CHMP is now referred to the European Commission for an approval decision. 